ABSTRACT
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new directacting antivirals—sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)— opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
- © 2014 The Cleveland Clinic Foundation. All Rights Reserved.
- Mohannad Dugum, MD and
- Robert O’shea, MD⇑
- Department of Internal Medicine, Medicine Institute, Cleveland Clinic
- Department of Gastroenterology and Hepatology, and Transplantation Center, Digestive Disease Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- ADDRESS:
Robert O’Shea, MD, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue / A30, Cleveland, OH 44195; e-mail: oshear{at}ccf.org
ABSTRACT
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new directacting antivirals—sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)— opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
- © 2014 The Cleveland Clinic Foundation. All Rights Reserved.